2-[4-(3-methoxyphenyl)butyl]phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[4-(3-methoxyphenyl)butyl]phenol
• 化学式: C₁₇H₂₀O₂
• 分子量: 256.345
• InChiKey: VTMAOKFGHJPQHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[4-(3-methoxyphenyl)butyl]phenol 在 lithium aluminium tetrahydride 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 4-{2-[4-(3-methoxyphenyl)butyl]phenoxy}-1-methylpiperidine
  参考文献：
  名称：

  [2-(.OMEGA.-Phenylalkyl)phenoxy]alkylamines: Synthesis and Dual Dopamine2 (D2) and 5-Hydroxytryptamine2 (5-HT2) Receptor Antagonistic Activities.

  摘要：

  一系列[2-(ω-苯基烷基)苯氧基]烷基胺被合成，并在体外检测了它们对5-羟色胺2 (5-HT2)和/或多巴胺2 (D2)受体的拮抗活性。[2-(4-苯基丁基)苯氧基]烷基胺显示出对5-HT2和D2受体的强烈抑制作用。特别是，[2-(4-苯基丁基)苯氧基]甲基哌啶衍生物，10b、10i和10q，表现出了强大的抑制作用。讨论了这一系列化合物的结构-活性关系。

  DOI：

  10.1248/cpb.46.639

文献信息

• [EN] COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：EXCIVA UG HAFTUNGSBESCHRAENKT

  公开号：WO2018039642A1

  公开（公告）日：2018-03-01

  Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: (IIa) (IIb) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.

  提供具有公式I的化合物(I)或其对应异构体、代谢物、衍生物、氘化衍生物、卤化衍生物、前药、药用可接受盐、N-氧化物或其组合，以及它们的制备过程和中间体、组合物和使用方法。包含公式I化合物的药物组合物以及公式II的化合物(IIa) (IIb)或其对应异构体、代谢物、衍生物、氘化衍生物、前药、药用可接受盐、N-氧化物或其组合。包含共给予需要该物质的受试者公式I化合物或SARPO和公式II化合物或DEX的DEX效能改进或提供DEX有益药代动力学效果的组合物和方法，以及剂量形式、药物传递系统、治疗方法。
• .alpha.-.omega.-diarylalkane compounds serotonin-2 receptor agonists
  申请人：Sankyo Company, Limited

  公开号：US05556864A1

  公开（公告）日：1996-09-17

  Compounds of formula (I): ##STR1## [wherein: R.sup.1 is aryl; R.sup.2 is hydrogen, alkyl, alkoxy, halogen or cyano; R.sup.3 is a group of formula --B--NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are independently hydrogen, alkyl or substituted alkyl or R.sup.4 and R.sup.5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula --CH.sub.2 CH(OR.sup.6)CH.sub.2 --, where R.sup.6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula --D--R.sup.7, where D is a single bond or alkylene and R.sup.7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of circulatory diseases and psychosis.

  化合物的化学式（I）：##STR1## [其中：R.sup.1是芳基；R.sup.2是氢、烷基、烷氧基、卤素或氰基；R.sup.3是化学式--B--NR.sup.4R.sup.5的基团，其中R.sup.4和R.sup.5独立地是氢、烷基或取代烷基或R.sup.4和R.sup.5与它们连接的氮一起形成杂环，B是烷基或化学式--CH.sub.2CH(OR.sup.6)CH.sub.2--的基团，其中R.sup.6是氢、烷酰基、取代烷酰基或芳基甲酰基，或化学式--D--R.sup.7的基团，其中D是单键或烷基且R.sup.7是杂环；A是烷基；以及其药学上可接受的盐和酯] 用于治疗和预防循环系统疾病和精神病。
• Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0600717A1

  公开（公告）日：1994-06-08

  Compounds of formula (I): [wherein: R¹ is aryl; R² is hydrogen, alkyl, alkoxy, halogen or cyano; R³ is a group of formula -B-NR⁴R⁵, where R⁴ and R⁵ are independently hydrogen, alkyl or substituted alkyl or R⁴ and R⁵, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula -CH₂CH(OR⁶ )CH₂-, where R⁶ is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula -D-R⁷, where D is a single bond or alkylene and R⁷ is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of circulatory diseases and psychosis.

  式(I)的化合物：[其中：R¹为芳基；R²为氢、烷基、烷氧基、卤素或氰基；R³为式-B-NR⁴R⁵的基团，其中R⁴和R⁵独立地为氢、烷基或取代烷基，或者R⁴和R⁵与它们所连接的氮一起形成杂环，B为烷基或式-CH₂CH(OR⁶)CH₂-的基团，其中R⁶为氢、烷酰基、取代烷酰基或芳基羰基，或式-D-R⁷的基团，其中D为单键或烷基烯丙基，R⁷为杂环；且A为烷基；以及其药学上可接受的盐和酯]可用于治疗和预防循环系统疾病和精神病。
• Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0844000A1

  公开（公告）日：1998-05-27

  Compounds of formula (I): [wherein: R1 is aryl; R2 is hydrogen, alkyl, alkoxy, halogen or cyano; R3 is a group of formula -B-NR4R5, where R4 and R5 are independently hydrogen, alkyl or substituted alkyl or R4 and R5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula -CH2CH(OR6)CH2-, where R6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula -D-R7, where D is a single bond or alkylene and R7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of psychosis.

  式(I)化合物： 其中R1 是芳基；R2 是氢、烷基、烷氧基、卤素或氰基；R3 是式-B-NR4R5 的基团，其中 R4 和 R5 独立地是氢、烷基或取代的烷基，或 R4 和 R5 与它们所连接的氮一起构成杂环，B 是亚烷基或式- CH(OR6)CH2-的基团，其中 R6 是氢、烷酰基、取代的烷酰基或芳羰基，或式-D-R7 的基团，其中 D 是单键或亚烷基，R7 是杂环；和 A 是亚烷基；及其药学上可接受的盐和酯]可用于治疗和预防精神病。
• COMPOSITIONS AND METHODS THEREOF
  申请人：Exciva UG (Haftungsbeschränkt)

  公开号：EP3503879A1

  公开（公告）日：2019-07-03